Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 113Colonic Neoplasms 30Neoplasm Metastasis 28Rectal Neoplasms 27Neoplasms 27Carcinoma, Non-Small-Cell Lung 14Esophageal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Head and Neck Neoplasms 9Lung Neoplasms 8Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Breast Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Prostatic Neoplasms 4Ovarian Neoplasms 4Inflammatory Breast Neoplasms 3Gastrointestinal Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Kidney Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2

Interventions

telotristat ethyl 4lanreotide 2telotristat 1pasireotide 1lutetium Lu 177 dotatate 1alpha-methyltryptophan 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Random Allocation 1Panitumumab 1Octreotide 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Serotonin Syndrome × Panitumumab × Clear all
NCT01172717 2013-07-26

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Boston Medical Center

Phase 2 Withdrawn
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡